Myelodysplastic Syndromes (MDS)

Transplant for Aplastic Anemia and MDS - 2024 Los Angeles Patient and Family Conference

Topic(s)

Bone Marrow Transplant

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

Presenter(s)

Ryotaro Nakamura, MD

Dr. Ryotaro Nakamura explains the entire process for bone marrow transplantation in this recorded session from the 2024 Los Angeles Patient and Family Conference. Learn the potential ways transplants can help patients with aplastic anemia or MDS.

Advances in Treating Lower Risk MDS - 2024 Los Angeles Patient and Family Conference

Thumbnail for video Watch Now

Topic(s)

Myelodysplastic Syndromes (MDS)

Presenter(s)

Brian Ball, MD

Learn about recent research and clinical advances for treating Low-Risk MDS, or Myelodysplastic Syndromes in this session from Dr. Brain Ball.

Emerging Therapies in High-Risk MDS - 2024 Los Angeles Patient and Family Conference

Thumbnail for video Watch Now

Topic(s)

Myelodysplastic Syndromes (MDS)

Presenter(s)

Zahra Pakbaz, MD

Discover the most recent treatments and therapies available for High-Risk MDS, or Myelodysplastic Syndromes, in this recorded session featuring Dr. Zahra Pakbaz.

SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes

Read more about SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes

Higher-risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders wh

Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies

Read more about Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies

Introduction: In patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLAS

Athletic Service Member Conquers Aplastic Anemia and MDS with Transplant

Biosimilars

Read more about Biosimilars

What is a Biosimilar?

A biosimilar is a type of biologic medication. The term “biosimilar” means that the medication is highly similar to the already approved brand name biologic (“originator” medication). Biosimilars are not generic versions of the original biologic.

Clinical Trials

Read more about Clinical Trials

Clinical research Clinical research: A type of research that involves individual persons or a group of people.

Romiplostim

Read more about Romiplostim

Romiplostim Romiplostim: Romiplostim is in a class of medications called thrombopoietin receptor agonists. It works by causing the cells in the bone marrow to produce more platelets.

Hydroxyurea

Read more about Hydroxyurea

Subscribe to Myelodysplastic Syndromes (MDS)

Your Gift Today Changes Lives

Myelodysplastic Syndromes (MDS)

Transplant for Aplastic Anemia and MDS - 2024 Los Angeles Patient and Family Conference

Advances in Treating Lower Risk MDS - 2024 Los Angeles Patient and Family Conference

Emerging Therapies in High-Risk MDS - 2024 Los Angeles Patient and Family Conference

SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes

Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies

Athletic Service Member Conquers Aplastic Anemia and MDS with Transplant

Biosimilars

What is a Biosimilar?

Clinical Trials

Romiplostim

Hydroxyurea

Website Feedback

Patient Helpline